12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Insights into the antiviral activity of phospholipases A 2 (PLA 2s) from snake venoms

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Viruses are associated with several human diseases that infect a large number of individuals, hence directly affecting global health and economy. Owing to the lack of efficient vaccines, antiviral therapy and emerging resistance strains, many viruses are considered as a potential threat to public health. Therefore, researches have been developed to identify new drug candidates for future treatments. Among them, antiviral research based on natural molecules is a promising approach. Phospholipases A 2 (PLA 2s) isolated from snake venom have shown significant antiviral activity against some viruses such as Dengue virus, Human Immunodeficiency virus, Hepatitis C virus and Yellow fever virus, and have emerged as an attractive alternative strategy for the development of novel antiviral therapy. Thus, this review provides an overview of remarkable findings involving PLA 2s from snake venom that possess antiviral activity, and discusses the mechanisms of action mediated by PLA 2s against different stages of virus replication cycle. Additionally, molecular docking simulations were performed by interacting between phospholipids from Dengue virus envelope and PLA 2s from Bothrops asper snake venom. Studies on snake venom PLA 2s highlight the potential use of these proteins for the development of broad-spectrum antiviral drugs.

          Related collections

          Most cited references105

          • Record: found
          • Abstract: found
          • Article: not found

          Emergence and pandemic potential of swine-origin H1N1 influenza virus.

          Influenza viruses cause annual epidemics and occasional pandemics that have claimed the lives of millions. The emergence of new strains will continue to pose challenges to public health and the scientific communities. A prime example is the recent emergence of swine-origin H1N1 viruses that have transmitted to and spread among humans, resulting in outbreaks internationally. Efforts to control these outbreaks and real-time monitoring of the evolution of this virus should provide us with invaluable information to direct infectious disease control programmes and to improve understanding of the factors that determine viral pathogenicity and/or transmissibility.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The SARS-CoV-2 outbreak: what we know

            Highlights • The latest summary of the COVID-19 outbreak in China. • There might be an oral-fecal transmission of the virus. • Aggregates and consolidates the epidemiology, clinical manifestations, diagnosis, treatments and preventions of this new type of coronavirus.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Influenza: old and new threats.

              Influenza remains an important disease in humans and animals. In contrast to measles, smallpox and poliomyelitis, influenza is caused by viruses that undergo continuous antigenic change and that possess an animal reservoir. Thus, new epidemics and pandemics are likely to occur in the future, and eradication of the disease will be difficult to achieve. Although it is not clear whether a new pandemic is imminent, it would be prudent to take into account the lessons we have learned from studying different human and animal influenza viruses. Specifically, reconstruction of the genes of the 1918 pandemic virus and studies on their contribution to virulence will be important steps toward understanding the biological capabilities of this lethal virus. Increasing the availability of new antiviral drugs and developing superior vaccines will provide us with better approaches to control influenza and to have a positive impact on disease load. A concern is that the imposition of new rules for working with infectious influenza viruses under high security and high containment conditions will stifle scientific progress. The complex questions of what makes an influenza virus transmissible from one human to another and from one species to another, as well as how the immune system interacts with the virus, will require the active collaboration and unencumbered work of many scientific groups.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Biol Macromol
                Int. J. Biol. Macromol
                International Journal of Biological Macromolecules
                Published by Elsevier B.V.
                0141-8130
                1879-0003
                19 July 2020
                19 July 2020
                Affiliations
                [a ]Department of Immunology, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, MG, Brazil
                [b ]Multidisciplinary Institute of Health, Anísio Teixeira Campus, Federal University of Bahia, Vitória da Conquista, BA, Brazil
                [c ]Laboratory of Virology, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, MG, Brazil
                [d ]Laboratory of Biochemistry and Animal Toxins, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil
                [e ]Institute of Health Sciences, Department of Bio-Function, Federal University of Bahia, Salvador, BA, Brazil
                Author notes
                [* ]Corresponding authors at: Multidisciplinary Institute of Health, Federal University of Bahia, Anísio Teixeira Campus, Vitória da Conquista-BA, Brazil. veridiana@ 123456ufu.br lsdaiana@ 123456yahoo.com.br
                Article
                S0141-8130(20)33934-9
                10.1016/j.ijbiomac.2020.07.178
                7368918
                32698062
                f3f38cef-dfad-4596-b260-ef2256cf78f6
                © 2020 Published by Elsevier B.V.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 27 May 2020
                : 8 July 2020
                : 14 July 2020
                Categories
                Article

                Biochemistry
                snake venom,phospholipases a2,virus,antiviral drugs
                Biochemistry
                snake venom, phospholipases a2, virus, antiviral drugs

                Comments

                Comment on this article